Regulatory Roche, Eli Lilly get FDA nod for new Alzheimer’s blood test BioPharma DiveLabcorp and Quest Diagnostics both plan to offer the test, which secured CE mark certification earlier this year.NeuroscienceRead full story pharminent August 25, 2026 (Last updated: August 26, 2026) BioPharma Dive Labcorp and Quest Diagnostics both plan to offer the test, which secured CE mark certification earlier this year. Neuroscience Read full story Post navigation Previous: China’s Haisco forms immunology biotech with up to $1.5B from American VCsNext: FDA Approves J&J’s Imaavy for Warm Autoimmune Hemolytic Anemia, the First Therapy Ever Cleared in the Disease Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026